{
    "xml": "<topic id=\"PHP1482\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/fondaparinux-sodium\" basename=\"fondaparinux-sodium\" title=\"FONDAPARINUX SODIUM\">\n<title>FONDAPARINUX SODIUM</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1314\" namespace=\"/interactions/list-of-drug-interactions/anticoagulants/fondaparinux\">Fondaparinux</xref>\n</p>\n<data name=\"vtmid\">395236007</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_541694731\" title=\"Factor Xa inhibitors\">Factor Xa inhibitors</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">   </data>\n</data>\r\n</body>\n<topic id=\"PHP60877\" outputclass=\"drugAction\" rev=\"1.11\" parent=\"/drugs/fondaparinux-sodium\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Fondaparinux sodium is a synthetic pentasaccharide that inhibits activated factor X.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60827\" outputclass=\"indicationsAndDose\" rev=\"1.54\" parent=\"/drugs/fondaparinux-sodium\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prophylaxis of venous thromboembolism in patients after undergoing major orthopaedic surgery of the hip or leg, or abdominal surgery</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 2.5&#8239;mg, dose to be given 6 hours after surgery, then 2.5&#8239;mg once daily.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prophylaxis of venous thromboembolism in medical patients immobilised because of acute illness</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>2.5&#8239;mg once daily.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of superficial-vein thrombosis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult (body-weight 50 kg and above)</p>\n<p>2.5&#8239;mg once daily for at least 30 days (max. 45 days if high risk of thromboembolic complications), treatment should be stopped 24 hours before surgery and restarted at least 6 hours post operatively.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of unstable angina and non-ST-segment elevation myocardial infarction</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>2.5&#8239;mg once daily for up to 8 days (or until hospital discharge if sooner), treatment should be stopped 24 hours before coronary artery bypass graft surgery (where possible) and restarted 48 hours post operatively.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of ST-segment elevation myocardial infarction</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">Initially by intravenous injection or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 2.5&#8239;mg daily for the first day, then (by subcutaneous injection) 2.5&#8239;mg once daily for up to 8 days (or until hospital discharge if sooner), treatment should be stopped 24 hours before coronary artery bypass graft surgery (where possible) and restarted 48 hours post operatively.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of deep-vein thrombosis and pulmonary embolism</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult (body-weight up to 50 kg)</p>\n<p>5&#8239;mg every 24&#8239;hours, an oral anticoagulant (usually warfarin) is started at the same time as fondaparinux (fondaparinux should be continued for at least 5 days and until INR &#8805; 2 for at least 24 hours).</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult (body-weight 50&#8211;100 kg)</p>\n<p>7.5&#8239;mg every 24&#8239;hours, an oral anticoagulant (usually warfarin) is started at the same time as fondaparinux (fondaparinux should be continued for at least 5 days and until INR &#8805; 2 for at least 24 hours).</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult (body-weight 101 kg and above)</p>\n<p>10&#8239;mg every 24&#8239;hours, an oral anticoagulant (usually warfarin) is started at the same time as fondaparinux (fondaparinux should be continued for at least 5 days and until INR &#8805; 2 for at least 24 hours).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60883\" outputclass=\"contraindications\" rev=\"1.7\" parent=\"/drugs/fondaparinux-sodium\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Active bleeding</ph>; <ph outputclass=\"contraindication\">bacterial endocarditis</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60905\" outputclass=\"cautions\" rev=\"1.15\" parent=\"/drugs/fondaparinux-sodium\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Active gastro-intestinal ulcer disease</ph>; <ph outputclass=\"caution\">bleeding disorders</ph>; <ph outputclass=\"caution\">brain surgery</ph>; <ph outputclass=\"caution\">elderly patients</ph>; <ph outputclass=\"caution\">low body-weight</ph>; <ph outputclass=\"caution\">ophthalmic surgery</ph>; <ph outputclass=\"caution\">recent intracranial haemorrhage</ph>; <ph outputclass=\"caution\">risk of catheter thrombus during percutaneous coronary intervention</ph>; <ph outputclass=\"caution\">spinal or epidural anaesthesia (risk of spinal haematoma&#8212;avoid if using treatment doses)</ph>; <ph outputclass=\"caution\">spinal surgery</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60822\" outputclass=\"interactions\" rev=\"1.17\" parent=\"/drugs/fondaparinux-sodium\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (fondaparinux).</p>\n<p>Caution with concomitant use of drugs that increase risk of bleeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60788\" outputclass=\"sideEffects\" rev=\"1.11\" parent=\"/drugs/fondaparinux-sodium\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Anaemia</ph>; <ph outputclass=\"sideEffect\">bleeding</ph>; <ph outputclass=\"sideEffect\">purpura</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Chest pain</ph>; <ph outputclass=\"sideEffect\">dyspnoea</ph>; <ph outputclass=\"sideEffect\">gastro-intestinal disturbances</ph>; <ph outputclass=\"sideEffect\">hepatic impairment</ph>; <ph outputclass=\"sideEffect\">oedema</ph>; <ph outputclass=\"sideEffect\">pruritus</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">thrombocythaemia</ph>; <ph outputclass=\"sideEffect\">thrombocytopenia</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Anxiety</ph>; <ph outputclass=\"sideEffect\">confusion</ph>; <ph outputclass=\"sideEffect\">cough</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">drowsiness</ph>; <ph outputclass=\"sideEffect\">flushing</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">hyperbilirubinaemia</ph>; <ph outputclass=\"sideEffect\">hypokalaemia</ph>; <ph outputclass=\"sideEffect\">hypotension</ph>; <ph outputclass=\"sideEffect\">injection-site reactions</ph>; <ph outputclass=\"sideEffect\">vertigo</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Atrial fibrillation</ph>; <ph outputclass=\"sideEffect\">pyrexia</ph>; <ph outputclass=\"sideEffect\">tachycardia</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60815\" outputclass=\"pregnancy\" parent=\"/drugs/fondaparinux-sodium\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid unless potential benefit outweighs possible risk&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60931\" outputclass=\"breastFeeding\" parent=\"/drugs/fondaparinux-sodium\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Present in milk in <i>animal</i> studies&#8212;manufacturer advises avoid.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60865\" outputclass=\"hepaticImpairment\" parent=\"/drugs/fondaparinux-sodium\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Caution in severe impairment (increased risk of bleeding).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60801\" outputclass=\"renalImpairment\" parent=\"/drugs/fondaparinux-sodium\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p outputclass=\"specificity\">When used for <ph outputclass=\"indication\">prophylaxis of venous thromboembolism and treatment of superficial-vein thrombosis</ph>\n</p>\n<p>Reduce dose to 1.5&#8239;mg daily if eGFR 20&#8211;50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p outputclass=\"specificity\">When used for <ph outputclass=\"indication\">treatment of acute coronary syndromes</ph> or <ph outputclass=\"indication\">prophylaxis of venous thromboembolism and treatment of superficial-vein thrombosis</ph>\n</p>\n<p>Avoid if eGFR less than 20&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">When used for <ph outputclass=\"indication\">treatment of venous thromboembolism</ph>\n</p>\n<p>Use with caution if eGFR 30&#8211;50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>, avoid if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Increased risk of bleeding in renal impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60978\" outputclass=\"directionsForAdministration\" rev=\"1.13\" parent=\"/drugs/fondaparinux-sodium\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>For <i>intravenous infusion</i> (<i>Arixtra</i>\n<tm tmtype=\"reg\"/>), give intermittently in Sodium chloride 0.9%. For ST-segment elevation myocardial infarction, add requisite dose to 25-50&#8239;mL infusion fluid and give over 1-2 minutes.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP1482-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/fondaparinux-sodium\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77361\" title=\"Solution for injection\" namespace=\"/drugs/fondaparinux-sodium/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78144\" namespace=\"/treatment-summaries/acute-coronary-syndromes\" title=\"Acute coronary syndromes\" count=\"3\" rel=\"backlink\">Acute coronary syndromes</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78403\" namespace=\"/treatment-summaries/venous-thromboembolism\" title=\"Venous thromboembolism\" count=\"2\" rel=\"backlink\">Venous thromboembolism</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1314\" namespace=\"/interactions/list-of-drug-interactions/anticoagulants/fondaparinux\" title=\"Fondaparinux\" count=\"1\" rel=\"link\">Fondaparinux</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77361\" namespace=\"/drugs/fondaparinux-sodium/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP1482",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/fondaparinux-sodium",
    "basename": "fondaparinux-sodium",
    "title": "FONDAPARINUX SODIUM",
    "interactants": [
        {
            "id": "bnf_int_1314",
            "label": "Fondaparinux"
        }
    ],
    "vtmid": "395236007",
    "drugClassification": [
        "Factor Xa inhibitors"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Fondaparinux sodium is a synthetic pentasaccharide that inhibits activated factor X.",
                "html": "<p>Fondaparinux sodium is a synthetic pentasaccharide that inhibits activated factor X.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Prophylaxis of venous thromboembolism in patients after undergoing major orthopaedic surgery of the hip or leg, or abdominal surgery",
                        "html": "Prophylaxis of venous thromboembolism in patients after undergoing major orthopaedic surgery of the hip or leg, or abdominal surgery"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 2.5 mg, dose to be given 6 hours after surgery, then 2.5 mg once daily.",
                        "html": "<p>Initially 2.5&#8239;mg, dose to be given 6 hours after surgery, then 2.5&#8239;mg once daily.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prophylaxis of venous thromboembolism in medical patients immobilised because of acute illness",
                        "html": "Prophylaxis of venous thromboembolism in medical patients immobilised because of acute illness"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "2.5 mg once daily.",
                        "html": "<p>2.5&#8239;mg once daily.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Treatment of superficial-vein thrombosis",
                        "html": "Treatment of superficial-vein thrombosis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "2.5 mg once daily for at least 30 days (max. 45 days if high risk of thromboembolic complications), treatment should be stopped 24 hours before surgery and restarted at least 6 hours post operatively.",
                        "html": "<p>2.5&#8239;mg once daily for at least 30 days (max. 45 days if high risk of thromboembolic complications), treatment should be stopped 24 hours before surgery and restarted at least 6 hours post operatively.</p>",
                        "ageGroup": "(body-weight 50 kg and above)"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Treatment of unstable angina and non-ST-segment elevation myocardial infarction",
                        "html": "Treatment of unstable angina and non-ST-segment elevation myocardial infarction"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "2.5 mg once daily for up to 8 days (or until hospital discharge if sooner), treatment should be stopped 24 hours before coronary artery bypass graft surgery (where possible) and restarted 48 hours post operatively.",
                        "html": "<p>2.5&#8239;mg once daily for up to 8 days (or until hospital discharge if sooner), treatment should be stopped 24 hours before coronary artery bypass graft surgery (where possible) and restarted 48 hours post operatively.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Treatment of ST-segment elevation myocardial infarction",
                        "html": "Treatment of ST-segment elevation myocardial infarction"
                    }
                ],
                "specificity": {
                    "routes": [
                        "Initially intravenous injection or intravenous infusion"
                    ],
                    "textContent": "Initially by intravenous injection or by intravenous infusion",
                    "html": "Initially by intravenous injection or by intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "Initially 2.5 mg daily for the first day, then (by subcutaneous injection) 2.5 mg once daily for up to 8 days (or until hospital discharge if sooner), treatment should be stopped 24 hours before coronary artery bypass graft surgery (where possible) and restarted 48 hours post operatively.",
                        "html": "<p>Initially 2.5&#8239;mg daily for the first day, then (by subcutaneous injection) 2.5&#8239;mg once daily for up to 8 days (or until hospital discharge if sooner), treatment should be stopped 24 hours before coronary artery bypass graft surgery (where possible) and restarted 48 hours post operatively.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Treatment of deep-vein thrombosis and pulmonary embolism",
                        "html": "Treatment of deep-vein thrombosis and pulmonary embolism"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "5 mg every 24 hours, an oral anticoagulant (usually warfarin) is started at the same time as fondaparinux (fondaparinux should be continued for at least 5 days and until INR &#8805; 2 for at least 24 hours).",
                        "html": "<p>5&#8239;mg every 24&#8239;hours, an oral anticoagulant (usually warfarin) is started at the same time as fondaparinux (fondaparinux should be continued for at least 5 days and until INR &#8805; 2 for at least 24 hours).</p>",
                        "ageGroup": "(body-weight up to 50 kg)"
                    },
                    {
                        "textContent": "7.5 mg every 24 hours, an oral anticoagulant (usually warfarin) is started at the same time as fondaparinux (fondaparinux should be continued for at least 5 days and until INR &#8805; 2 for at least 24 hours).",
                        "html": "<p>7.5&#8239;mg every 24&#8239;hours, an oral anticoagulant (usually warfarin) is started at the same time as fondaparinux (fondaparinux should be continued for at least 5 days and until INR &#8805; 2 for at least 24 hours).</p>",
                        "ageGroup": "(body-weight 50&#8211;100 kg)"
                    },
                    {
                        "textContent": "10 mg every 24 hours, an oral anticoagulant (usually warfarin) is started at the same time as fondaparinux (fondaparinux should be continued for at least 5 days and until INR &#8805; 2 for at least 24 hours).",
                        "html": "<p>10&#8239;mg every 24&#8239;hours, an oral anticoagulant (usually warfarin) is started at the same time as fondaparinux (fondaparinux should be continued for at least 5 days and until INR &#8805; 2 for at least 24 hours).</p>",
                        "ageGroup": "(body-weight 101 kg and above)"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Active bleeding",
                "html": "Active bleeding"
            },
            {
                "type": "contraindications",
                "textContent": "bacterial endocarditis",
                "html": "bacterial endocarditis"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Active gastro-intestinal ulcer disease",
                "html": "Active gastro-intestinal ulcer disease"
            },
            {
                "type": "cautions",
                "textContent": "bleeding disorders",
                "html": "bleeding disorders"
            },
            {
                "type": "cautions",
                "textContent": "brain surgery",
                "html": "brain surgery"
            },
            {
                "type": "cautions",
                "textContent": "elderly patients",
                "html": "elderly patients"
            },
            {
                "type": "cautions",
                "textContent": "low body-weight",
                "html": "low body-weight"
            },
            {
                "type": "cautions",
                "textContent": "ophthalmic surgery",
                "html": "ophthalmic surgery"
            },
            {
                "type": "cautions",
                "textContent": "recent intracranial haemorrhage",
                "html": "recent intracranial haemorrhage"
            },
            {
                "type": "cautions",
                "textContent": "risk of catheter thrombus during percutaneous coronary intervention",
                "html": "risk of catheter thrombus during percutaneous coronary intervention"
            },
            {
                "type": "cautions",
                "textContent": "spinal or epidural anaesthesia (risk of spinal haematoma&#8212;avoid if using treatment doses)",
                "html": "spinal or epidural anaesthesia (risk of spinal haematoma&#8212;avoid if using treatment doses)"
            },
            {
                "type": "cautions",
                "textContent": "spinal surgery",
                "html": "spinal surgery"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (fondaparinux).\n\nCaution with concomitant use of drugs that increase risk of bleeding.",
                "html": "<p>Appendix 1 (fondaparinux).</p><p>Caution with concomitant use of drugs that increase risk of bleeding.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Anaemia",
                        "html": "Anaemia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "bleeding",
                        "html": "bleeding",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "purpura",
                        "html": "purpura",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Chest pain",
                        "html": "Chest pain",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "dyspnoea",
                        "html": "dyspnoea",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "gastro-intestinal disturbances",
                        "html": "gastro-intestinal disturbances",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "hepatic impairment",
                        "html": "hepatic impairment",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "oedema",
                        "html": "oedema",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "pruritus",
                        "html": "pruritus",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "thrombocythaemia",
                        "html": "thrombocythaemia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "thrombocytopenia",
                        "html": "thrombocytopenia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Anxiety",
                        "html": "Anxiety",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "confusion",
                        "html": "confusion",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "cough",
                        "html": "cough",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "drowsiness",
                        "html": "drowsiness",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "flushing",
                        "html": "flushing",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "hyperbilirubinaemia",
                        "html": "hyperbilirubinaemia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "hypokalaemia",
                        "html": "hypokalaemia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "hypotension",
                        "html": "hypotension",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "injection-site reactions",
                        "html": "injection-site reactions",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "vertigo",
                        "html": "vertigo",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Atrial fibrillation",
                        "html": "Atrial fibrillation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pyrexia",
                        "html": "pyrexia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tachycardia",
                        "html": "tachycardia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid unless potential benefit outweighs possible risk&#8212;no information available.",
                "html": "<p>Manufacturer advises avoid unless potential benefit outweighs possible risk&#8212;no information available.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Present in milk in animal studies&#8212;manufacturer advises avoid.",
                "html": "<p>Present in milk in <i>animal</i> studies&#8212;manufacturer advises avoid.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Caution in severe impairment (increased risk of bleeding).",
                "html": "<p>Caution in severe impairment (increased risk of bleeding).</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "specificity": {
                    "textContent": "When used for prophylaxis of venous thromboembolism and treatment of superficial-vein thrombosis",
                    "html": "When used for <ph outputclass=\"indication\">prophylaxis of venous thromboembolism and treatment of superficial-vein thrombosis</ph>",
                    "patientType": "thrombosis",
                    "indications": [
                        "prophylaxis of venous thromboembolism and treatment of superficial-vein thrombosis"
                    ]
                },
                "textContent": "Reduce dose to 1.5 mg daily if eGFR 20&#8211;50 mL/minute/1.73 m2.",
                "html": "<p>Reduce dose to 1.5&#8239;mg daily if eGFR 20&#8211;50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "specificity": {
                    "textContent": "When used for treatment of acute coronary syndromes or prophylaxis of venous thromboembolism and treatment of superficial-vein thrombosis",
                    "html": "When used for <ph outputclass=\"indication\">treatment of acute coronary syndromes</ph> or <ph outputclass=\"indication\">prophylaxis of venous thromboembolism and treatment of superficial-vein thrombosis</ph>",
                    "patientType": "thrombosis",
                    "indications": [
                        "treatment of acute coronary syndromes",
                        "prophylaxis of venous thromboembolism and treatment of superficial-vein thrombosis"
                    ]
                },
                "textContent": "Avoid if eGFR less than 20 mL/minute/1.73 m2.",
                "html": "<p>Avoid if eGFR less than 20&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>"
            },
            {
                "type": "generalInformation",
                "specificity": {
                    "textContent": "When used for treatment of venous thromboembolism",
                    "html": "When used for <ph outputclass=\"indication\">treatment of venous thromboembolism</ph>",
                    "indications": [
                        "treatment of venous thromboembolism"
                    ]
                },
                "textContent": "Use with caution if eGFR 30&#8211;50 mL/minute/1.73 m2, avoid if eGFR less than 30 mL/minute/1.73 m2.",
                "html": "<p>Use with caution if eGFR 30&#8211;50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>, avoid if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>"
            },
            {
                "type": "generalInformation",
                "textContent": "Increased risk of bleeding in renal impairment.",
                "html": "<p>Increased risk of bleeding in renal impairment.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "For intravenous infusion (Arixtra ), give intermittently in Sodium chloride 0.9%. For ST-segment elevation myocardial infarction, add requisite dose to 25-50 mL infusion fluid and give over 1-2 minutes.",
                "html": "<p>For <i>intravenous infusion</i> (<i>Arixtra</i>\n<tm tmtype=\"reg\"/>), give intermittently in Sodium chloride 0.9%. For ST-segment elevation myocardial infarction, add requisite dose to 25-50&#8239;mL infusion fluid and give over 1-2 minutes.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77361",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78144",
                "label": "Acute coronary syndromes",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78403",
                "label": "Venous thromboembolism",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1314",
                "label": "Fondaparinux",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77361",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}